Skip to Content
  • Revenues ($M)
  • Revenue Percent Change
  • Profits ($M)
  • Profits Percent Change
  • Assets ($M)
  • Employees
  • Market Value — as of March 31, 2016 ($M)
  • Previous Rank
  • Morning Consult Brand Index

Revenue for the 165-year-old drug maker slid 6.5% in 2015 largely due to currency fluctuations and divestitures. In the U.S., sales grew on the strong performance of its diabetes and cancer medications and as a result of its $8.3 billion acquisition of antibiotic maker Cubist Pharmaceuticals. The company also pressed ahead with restructuring efforts–it shed 2,000 jobs in 2015–and kept pace in the industry immunotherapy race, with the widening range of approved uses for Keytruda, Merck’s breakthrough immuno-oncology drug.

Company Info

Kenneth C. Frazier
Health Care
HQ Location
Kenilworth, NJ
Years on Fortune 500 List22
Created with sketchtool.Created with sketchtool.Looking for leads, investment insights, or competitive intelligence?Purchase Now

Key Financials (last fiscal year)

$ millions% change
Revenues ($M)$39,498-6.5%
Profits ($M)$4,442-62.7%
Assets ($M)$101,779-
Total Stockholder Equity ($M)$44,676-
Market Value — as of March 31, 2016 ($M)$146,839-

Profit Ratios

Profit as % of Revenues11.2%
Profits as % of Assets4.4%
Profits as % of Stockholder Equity9.9%

Earnings Per Share (Last Fiscal Year)

Earnings Per Share ($)1.56
EPS % Change (from 2014)-61.7%
EPS % Change (5 year annual rate)41%
EPS % Change (10 year annual rate)-2.9%

Total Return

Total Return to Investors (2015)-4%
Total Return to Investors (5 year, annualized)12%
Total Return to Investors (10 year, annualized)9.4%